Erschienen in:
24.03.2017 | New Technology
Laparoscopic image-based navigation for microwave ablation of liver tumors—A multi-center study
Laparoscopic navigation for hepatic ablation
verfasst von:
Pascale Tinguely, Matteo Fusaglia, Jacob Freedman, Vanessa Banz, Stefan Weber, Daniel Candinas, Henrik Nilsson
Erschienen in:
Surgical Endoscopy
|
Ausgabe 10/2017
Einloggen, um Zugang zu erhalten
Abstract
Background
Stereotactic navigation technology has been proposed to augment accuracy in targeting intrahepatic lesions for local ablation therapy. This retrospective study evaluated accuracy, efficacy, and safety when using laparoscopic image-guided microwave ablation (LIMA) for malignant liver tumors.
Methods
All patients treated for malignant liver lesions using LIMA at two European centers between 2013 and 2015 were included for analysis. A landmark-based registration technique was applied for intraoperative tumor localization and positioning of ablation probes. Intraoperative efficiency of the procedure was measured as number of registration attempts and time needed to achieve sufficient registration accuracy. Technical accuracy was assessed as Fiducial Registration Error (FRE). Outcome at 90 days including mortality, postoperative morbidity, rates of incomplete ablations, and early intrahepatic recurrences were reported.
Results
In 34 months, 54 interventions were performed comprising a total of 346 lesions (median lesions per patient 3 (1–25)). Eleven patients had concomitant laparoscopic resections of the liver or the colorectal primary tumor. Median time for registration was 4:38 min (0:26–19:34). Average FRE was 8.1 ± 2.8 mm. Follow-up at 90 days showed one death, 24% grade I/II, and 4% grade IIIa complications. Median length of hospital stay was 2 days (1–11). Early local recurrence was 9% per lesion and 32% per patient. Of these, 63% were successfully re-ablated within 6 months.
Conclusions
LIMA does not interfere with the intraoperative workflow and results in low complication and early local recurrence rates, even when simultaneously targeting multiple lesions. LIMA may represent a valid therapy option for patients with extensive hepatic disease within a multimodal treatment approach.